Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

June 28, 2013

Plandai Products Offer Aid for Summertime Skin Ailments

There is a somewhat jaded contemporary adage that states: “It is better to look good than to feel good.” While this saying is used throughout the year, with the passing of time, it seems to be taken literally by more and more people obsessed with their appearance or those seeking the elusive fountain of youth.  Moreover, once summertime lands and appearance-obsessed men and women are vying for that perfect skin, they tend to get more trouble than they bargained for.  It is a good thing that Plandaí­ Biotechnology (OTCBB: PLPL), may offer products that can be adapted to treat various skin ailments and conditions caused by excessive time in the sun. The Company is a developer of highly bioavailable, phytonutrient rich extracts utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

For example, In several scientific studies, green tea extract demonstrated an ability to neutralize the damage done by exposure to UV rays.  For example, a study by Case Western Reserve University showed that green tea potentially protects against sunburn. In this unusual study, subjects had green tea extract applied to the skin on their buttocks, which was then exposed to solar radiation. At a concentration level of 4 milligrams per 2.5 cm square of skin area, the volunteers obtained complete protection from sunburn. Some protection was also observed at lower concentrations down to 1 milligram per cm square of skin area.

Separately, a 2003 study performed at the Medical College of Georgia Department of Oral Biology, found that green tea had the ability to rejuvenate old skin cells that were at the end of their life cycle of 28 days. At certain concentrations, EGCG or a mixture of the major green tea polyphenols, stimulated aged keratinocytes to generate biological energy and to synthesize DNA, possibly for renewed cell division.

Plandaí­ has spent over a decade developing its Phytofare™ Catechin Complex, which is processed to deliver a natural, antioxidant-rich product that contains the full range of green tea catechins at a bioavailability level many times that of other products available on the market. They are currently testing a nano-encapsulated version of the Phytofare™ product in a topical application specifically to assess depth of penetration in anticipation of reaching out to anti-aging product manufacturers.  The Company’s Phytofare™ Nutricare product line is slated for launch in the fourth quarter of 2013 and as additional applications for its products are discovered and developed, Plandai’s product flexibility superiority will no doubt drive its revenue and earnings growth.

For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. 

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party.  All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.